COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

1,149

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

March 4, 2021

Study Completion Date

September 21, 2021

Conditions
COVID-19
Interventions
DRUG

REGN10933+REGN10987 combination therapy

Administered IV or SC single dose

DRUG

Placebo

Administered IV or SC single dose to match

Trial Locations (57)

10037

Regeneron Study Site, New York

10451

Regeneron Study Site, The Bronx

19140

Regeneron Study Site, Philadelphia

20037

Regeneron Study Site, Washington D.C.

21201

Regeneron Study Site, Baltimore

22042

Regeneron Study Site, Falls Church

27705

Regeneron Study Site, Durham

28209

Regeneron Study Site, Charlotte

28401

Regeneron Study Site, Wilmington

29325

Regeneron Study Site, Clinton

29425

Regeneron Study Site, Charleston

30322

Regeneron Study Site, Atlanta

31904

Regeneron Study Site, Columbus

32720

Regeneron Study Site, DeLand

32751

Regeneron Study Site, Maitland

32789

Regeneron Study Site, Winter Park

33010

Regeneron Study Site, Hialeah

33012

Regeneron Study Site, Hialeah

33126

Regeneron Study Site, Miami

33184

Regeneron Study Site, Miami

33407

Regeneron Study Site, West Palm Beach

33606

Regeneron Study Site, Tampa

33705

Regeneron Study Site, St. Petersburg

33880

Regeneron Study Site, Winter Haven

34982

Regeneron Study Site, Ft. Pierce

43215

Regeneron Study Site, Columbus

45409

Regeneron Study Site, Dayton

45432

Regeneron Study Site, Dayton

52242

Regeneron Study Site, Iowa City

60515

Regeneron Study Site, Downers Grove

70072

Regeneron Study Site, Marrero

70601

Regeneron Study Site, Lake Charles

71118

Regeneron Study Site, Shreveport

75154

Regeneron Study Site, Red Oak

75701

Regeneron Study Site, Tyler

77008

Regeneron Study Site, Houston

77030

Regeneron Study Site, Houston

77057

Regeneron Study Site, Houston

77093

Regeneron Study Site, Houston

77372

Regeneron Study Site, Splendora

77584

Regeneron Study Site, Pearland

78249

Regeneron Study Site, San Antonio

78413

Regeneron Study Site, Corpus Christi

79109

Regeneron Study Site, Amarillo

80907

Regeneron Study Site, Colorado Springs

85210

Regeneron Study Site, Mesa

85712

Regeneron Study Site, Tucson

89109

Regeneron Study Site, Las Vegas

90036

Regeneron Study Site, Los Angeles

90274

Regeneron Study Site, Rolling Hills Estates

90404

Regeneron Study Site, Santa Monica

90806

Regeneron Study Site, Long Beach

91303

Regeneron Study Site, Canoga Park

94127

Regeneron Study Site, San Francisco

94305

Regeneron Study Site, Stanford

50010-3014

Regeneron Study Site, Ames

07666

Regeneron Study Site, Teaneck

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04666441 - COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection | Biotech Hunter | Biotech Hunter